Objective: Adolescent men who have sex with men (AMSM) have high HIV incidence and low rates of HIV testing and pre-exposure prophylaxis (PrEP) use. There are few evidence-based HIV prevention programs that meet the unique needs of AMSM. The sequential, multiple assignment, randomized trial (SMART) program is a stepped care package of increasingly intensive eHealth interventions that were developed specifically for English- and Spanish-speaking AMSM. The sequence included universal sexuality education (SMART Sex Ed), an automated motivation and behavioral skills focused intervention (SMART Squad), and motivational interviewing via videoconferencing (SMART Sessions).
Method: This SMART compared HIV testing, PrEP use, condomless anal sex (CAS), condom use intentions, and condom use self-efficacy outcomes for different embedded treatment sequences in the SMART program among a large sample of English- and Spanish-speaking AMSM (ages 13-18) in the U.S. states and territories (N = 1,306).
Results: In most of the embedded treatment sequences, there were significant improvements across 12 months for most of the outcomes, including CAS with casual partners, HIV testing, PrEP use, and condom use self-efficacy. There were largely no changes in CAS inclusive of serious partnerships and condom use intentions declined in some regimes.
Conclusion: Findings from 12 months of follow-up provide evidence of the SMART program's long-term effectiveness, with particular benefits for the important outcomes of HIV testing and PrEP use. Given the lack of effective interventions for this high HIV-incidence population coupled with the potential for high reach given the eHealth modality, funders should put in place the resources to enable rapid implementation. (PsycInfo Database Record (c) 2025 APA, all rights reserved).
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1037/hea0001471 | DOI Listing |
Int J STD AIDS
March 2025
MAP Centre for Urban Health Solutions, St. Michael's Hospital, Toronto, ON, Canada.
BackgroundHepatitis B virus (HBV) disproportionately affects people at risk of HIV. Encounters for HIV post-exposure prophylaxis (PEP) create opportunities for HBV screening and prevention. We quantified HBV prevalence, susceptibility, and active/passive immunization use among patients seeking HIV PEP.
View Article and Find Full Text PDFAIDS Res Ther
March 2025
Department of Public Health, Adama Hospital Medical College, Adama, Oromia, Ethiopia.
Introduction: Antiretroviral therapy (ART) has significantly reduced HIV infections, but late initiation remains a major issue. This study aimed to identify predictors of ART initiation among newly diagnosed HIV-positive patients in Adama town.
Method: A retrospective cohort study was conducted, with 396 newly diagnosed HIV-positive patients.
AIDS Res Ther
March 2025
Joint Clinical Research Center, Plot 101 Lubowa Hill, Kampala, Uganda.
Background: With the current elimination of mother to child transmission (EMTCT) of HIV, the number of HIV-positive newborns has greatly reduced. Some countries have successfully eliminated HIV infections among newborn babies.
Methods: This study was nested within the DRIBS (Drug Resistance testing among Infants at Baseline Study), which enrolled 100 infants at the time of treatment initiation between 2017 and 2023.
BMC Public Health
March 2025
School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China.
Background: HIV testing among women in sub-Saharan Africa varies widely, with Sierra Leone having lower rates than other countries. This study explores geographic variations and determinants of HIV testing among women aged 15-49 in Sierra Leone.
Method: The study utilized data from the 2008, 2013, and 2019 Sierra Leone Demographic Health Surveys, comprising 39,606 women aged 15-49.
BMC Infect Dis
March 2025
Cancer Center, Department of Pulmonary and Critical Care Medicine, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, 310014, Zhejiang, China.
Background: Talaromycosis is an aggressive and life-threatening disease, caused by the pathogen Talaromyces marneffei (T. marneffei) which was first isolated from the bamboo rats (Rhizomys sinensis). T.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!